ClinicalTrials.gg
TerminatedNCT02762383Updated Sep 7, 2016

Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT)

A Phase 3 interventional study of Peginterferon Alfa-2 in HIV/HCV Coinfection, sponsored by Hoffmann-La Roche. Terminated at 10 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-07.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Why this study was terminated
Low recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is an uncontrolled, open-label, Phase III trial of peginterferon alfa-2a (Pegasys) in participants coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Participants with HIV/HCV who do not show negative or reduced HCV ribonucleic acid (RNA) after at least 12 weeks of treatment with peginterferon alfa-2a plus ribavirin will receive a low dose of peginterferon alfa-2a for 18 months. The primary objective is to evaluate safety and tolerability. Secondary objectives are to evaluate histological, virological, and biochemical effects.

02

Conditions studied

  • HIV/HCV Coinfection

Browse trials for

03

In context

Coinfection

92 studies on the registry are indexed under Coinfection; 12 are open to participants now.

This study's enrollment of 19 is below the median of 75 across 50 interventional studies indexed under Coinfection.

Browse Coinfection studies →

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Serologic evidence of chronic infection by anti-HCV antibody test
  • Received peginterferon alfa-2a for at least 12 weeks and either did not reach a 2-log drop in HCV RNA after 12 weeks of treatment, did not reach an undetectable HCV RNA after 24 weeks of treatment, or reached undetectable HCV RNA that was detectable again at the end of 48 weeks of treatment
  • Detectable serum HCV RNA at Screening
  • Serologic evidence of infection by HIV RNA detection
  • greater than or equal to (>/=) 100 cells/mcL during therapy with peginterferon alfa-2a plus ribavirin for at least 12 weeks
  • Stable HIV status and, if on antiretroviral therapy, a stable regimen for at least 6 weeks prior to Baseline
  • Compensated liver disease
  • No evidence of hepatocellular carcinoma

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Antineoplastic or immunomodulatory treatment within 6 months prior to first dose
  • Any drug within 6 weeks prior to first dose
  • Positive for hepatitis A immunoglobulin M antibody
  • Severe neutropenia or thrombocytopenia at Screening while still on therapy with peginterferon alfa-2a plus ribavirin
  • Severe psychiatric or neurologic comorbidity
  • History of any significant medical conditions, such as immune disorders or disease of the major organ systems
  • Uncontrolled thyroid disease
  • Severe retinopathy
  • Evidence of drug abuse
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Peginterferon Alfa-2a

    Participants will receive a low dose of peginterferon alfa-2a for 18 months.

    Drug: Peginterferon Alfa-2

Interventions

  • Peginterferon alfa-2a will be administered as 90 micrograms (mcg) via subcutaneous (SC) injection once weekly.

    Also known as: Pegasys

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Adverse Events (AEs)

    Time frame: From Baseline to end of treatment (up to 18 months)

Secondary outcomes

  1. Percentage of Participants with Histological Response According to Paired Biopsy

    Time frame: At end of treatment (up to 18 months)

  2. HIV RNA Viral Load in Copies per Milliliter (copies/mL)

    Time frame: At end of treatment (up to 18 months)

  3. Cluster of Differentiation (CD) 4 Cell Count in Cells per Microliter (cells/mcL)

    Time frame: At end of treatment (up to 18 months)

  4. Percentage of Participants with Virological Response According to HCV RNA Viral Load

    Time frame: At 6, 12, and 18 months during treatment, and at 24 weeks after end of treatment (up to 2 years overall)

  5. Percentage of Participants with Biochemical Response According to Alanine Aminotransferase (ALT) Level

    Time frame: At end of treatment (up to 18 months)

  6. Percentage of Participants with Sustained Biochemical Response According to ALT Level

    Time frame: At 24 weeks after end of treatment (up to 2 years overall)

07

Study locations

10 sites
  • Bruxelles, 1000, Belgium
  • Bruxelles, 1020, Belgium
  • Bruxelles, 1070, Belgium
  • Bruxelles, 1090, Belgium
  • Bruxelles, 1200, Belgium
  • Charleroi, 6000, Belgium
  • Edegem, 2650, Belgium
  • Gent, 9000, Belgium
  • Leuven, 3000, Belgium
  • Liege, 4000, Belgium
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2016
First posted
May 4, 2016
Start
Mar 2005
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Last update
Sep 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02762383
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 4, 2016
Start date
Mar 2005
Primary completion
Jun 2009
Completion
Jun 2009
Last update
Sep 7, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2a

Start the discussion